bexarotene has been researched along with amyloid beta-peptides in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bena, J; Cummings, JL; Devous, M; Heaney, C; Joshi, A; Kinney, JW; Moll-Tudla, J; Pontecorvo, M; Tang, A; Zhong, K | 1 |
| Casali, BT; Landreth, GE; Reed-Geaghan, EG | 1 |
1 trial(s) available for bexarotene and amyloid beta-peptides
| Article | Year |
|---|---|
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Apolipoproteins E; Bexarotene; Double-Blind Method; Female; Humans; Male; Middle Aged; Peptide Fragments; Positron-Emission Tomography; Retinoid X Receptors; Tetrahydronaphthalenes; Treatment Outcome | 2016 |
1 other study(ies) available for bexarotene and amyloid beta-peptides
| Article | Year |
|---|---|
Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Bexarotene; Cells, Cultured; Cognition; Cognition Disorders; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Transgenic; Peptide Fragments; Plaque, Amyloid; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors | 2018 |